Pfizer makes $10.6 billion cancer bet in cash deal for Array Biopharma

Pfizer Inc on Monday said it would buy Array Biopharma Inc for $10.64 billion in cash, a deal it hopes will help make it a leader in colon cancer and build up its pipeline of oncology drugs.